Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.68 |
| ▸ | BRD4 | O60885 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | GALR3 | O60755 | 2/20 | 0.55 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | DHFR | P00374 | 1/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.49 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.49 |
| ▸ | DCTPP1 | Q9H773 | 3/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.49 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL617824 | 0.88 | TNF (0.68) | TNFBRD4KDM4EALDH1A1HPGD | |
| SCHEMBL6170842 | 0.83 | TNF (0.56) | TNFBRD4KDM4EALDH1A1HPGD | |
| SCHEMBL317642 | 0.82 | DCTPP1 (0.70) | TNFBRD4KDM4EALDH1A1GALR3 | |
| SCHEMBL3974904 | 0.82 | TNF (0.77) | TNFKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5863348 | 0.82 | KDM4E (0.81) | BRD4KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL231295 | 0.81 | TNF (1.00) | TNFKDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL17380972 | 0.80 | DCTPP1 (0.69) | TNFBRD4KDM4EALDH1A1GALR3 | |
| SCHEMBL615475 | 0.80 | KDM4E (0.73) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL6169195 | 0.79 | TNF (0.62) | TNFBRD4HSD17B10GALR3NR2F2 | |
| SCHEMBL19019532 | 0.77 | TNF (0.52) | TNFBRD4KDM4EALDH1A1GALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041207-A1 | Compound | STERIX LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20110009448-A1 | Compound | STERIX LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-7786152-B2 | Compound | STERIX LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | STERIX LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-7309715-B2 | Compound | STERIX LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| EP-1556040-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | Sterix Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20040143124-A1 | Compound | STERIX LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| WO-2004037251-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | STERIX LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | HSD11B1, HSD3B1, HSD11B2 | TNF 1599/4885BRD4 1799/4885KDM4E 2033/4885 |
| US-20110009448-A1 | Compound | NR4A1, GPR6, PRMT6 | TNF 3386/4885BRD4 795/4885KDM4E 565/4885 |
| US-20120041207-A1 | Compound | NR4A1, GPR6, PRMT6 | TNF 3386/4885BRD4 795/4885KDM4E 565/4885 |
| US-20040143124-A1 | Compound | NR4A1, CBR1, NR2C2 | TNF 4150/4885BRD4 1215/4885KDM4E 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.